TMTiago Macedo

Tiago Macedo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tiago Macedo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Human iPSCs derived from cryopreserved testicular somatic cells enable germline regeneration in childhood cancer survivors

    by Tiago Macedo, Claudia De Guidi, Leah Nic Aodha, Nageswara Rao Boggavarapu, Maja Piechocka, Xuan Ye, Francesca Mastropasqua, Victoria Keros, Ulrika Norén Nyström, Per Frisk, et al.

    STUDY QUESTION: Can cryopreserved primary testicular somatic cells from childhood cancer survivors with severely decreased fertility potential be reprogrammed into human induced pluripotent stem cells (hiPSCs) competent for efficient specification into early human germ cells? SUMMARY ANSWER: Primary testicular somatic cells from cryopreserved testicular samples with severely compromised spermatogonial pools can be reprogrammed into hiPSCs using a non-genome-integrating, feeder-free approach and subsequently differentiated into human primordial germ cell-like cells (hPGCLCs) with high efficiency. WHAT IS KNOWN ALREADY: Infertility is one of the most concerning long-term side effects of cancer therapy in prepubertal boys, yet it remains largely unaddressed. Worldwide, biobanks storing cryopreserved immature testicular tissue are expanding to support the development of fertility preservation strategies, including future tissue and cell transplantation approaches. However, whether these samples can also serve as starting material to generate hiPSCs and subsequently differentiated into in vitro-derived germ cells remains largely unexplored. Currently, there are established protocols for non-genome-integrating reprogramming of somatic cells into hiPSCs and for hPGCLC specification that could be applied to cryopreserved testicular tissue, with special relevance for patient samples severely depleted of germ cells. STUDY DESIGN, SIZE, DURATION: Two biological replicates of cryopreserved prepubertal testicular tissue were used to obtain primary somatic cells, which were reprogrammed into hiPSCs and subsequently differentiated into hPGCLCs. This experimental pipeline had a duration of approximately four months. PARTICIPANTS/MATERIALS, SETTING, METHODS: Cryopreserved testicular tissue samples were obtained from two prepubertal cancer patients (6.2 and 6.3 years old) with depleted spermatogonial pools (spermatogonia count per round tubular cross-section of 0.04 and 0.02, and age-standardized Z-scores of − 17.62 and −20.48). These samples were subsequently used to derive primary testicular somatic cell cultures, which were then reprogrammed into hiPSCs using a clinically compatible, non-genome-integrating mRNA-based method under feeder-free conditions. The resulting hiPSC lines were validated and subsequently differentiated into hPGCLCs using two different specification protocols. The transcriptomic profiles of the hiPSCs and their derived hPGCLCs were verified using bulk RNA sequencing. MAIN RESULTS AND THE ROLE OF CHANCE: Here, we present the first successful generation of hiPSCs from cryopreserved testicular somatic cells of childhood cancer patients with a severely depleted germ cell pool. We accomplished this using a non-genome-integrating mRNA-based reprogramming approach. We further demonstrated the specification of hPGCLCs from these patient-derived hiPSCs, effectively regenerating their germline. This provides proof-of-concept for a stem cell-based fertility regeneration strategy in childhood cancer survivors with non-functional or absent germ cells. LARGE SCALE DATA: N/A LIMITATIONS, REASONS FOR CAUTION: This proof-of-concept study was limited by a small sample size, due to the restricted access to cryopreserved human prepubertal testicular tissues. Although multiple hiPSC clones were generated per individual, only one clone per patient was used for downstream analyses, precluding systematic assessment of intra-individual clonal variability, which remains an important aspect for future studies. While G-banding karyotyping was sufficient to validate genomic integrity in this proof‑of‑concept study, more comprehensive genetic and epigenetic analyses should be prioritized in future hiPSC and hPGCLC validation before any clinical application is considered. WIDER IMPLICATIONS OF THE FINDINGS: Childhood cancer patient-derived hiPSCs represent a powerful platform to investigate and address a broad range of long-term, cancer therapy-related complications. These hiPSCs and their derived germ cells may be used not only to develop in vitro gametogenesis protocols, but also to investigate mechanisms of cancer therapy toxicity and resistance among different patients, to identify early biomarkers of adverse outcomes, and to screen for germ cell protective agents. Importantly, cancer patient-specific hiPSCs have applications that extend well beyond germline, enabling regenerative strategies targeting other treatment-related sequelae through the generation of relevant somatic cell types. STUDY FUNDING/COMPETING INTEREST(S): T.M. was supported by the Erasmus+ program, as part of the projects WORK4ALL 2023 and WORK4ALL 2024 (2023-1-PT01-KA131-HED-000121324 and 2024-1-PT01-KA131-HED-000214636). J.P.A.-L. was supported by a Starting Grant in Medicine and Health (2022-01467) from the Swedish Research Council and Birgitta, the Carl-Axel Rydbeck Research Grant 2024 (2024- 00208), and the Scientific Fund Willy Gepts. Y.B. was supported by the Scientific Fund Willy Gepts. K.J. was supported by the Foundation for Pediatric Research, the Finnish Cancer Society, the Swedish Childhood Cancer Foundation (KP2020-0012), and the Birgitta and Carl-Axel Rydbeck’s Research Grant for Paediatric Research (2020-00335, 2021-00079, and 2023-00380). J.-B.S. was supported by the Swedish Childhood Cancer Fund (PR2019-0123; PR2022-0115; TJ2020-0023), and the Swedish Research Council (2018-03094; 2021-02107). All authors declare no conflict of interest.


  • Open Access

    The road to restore male fertility using in vitro -derived germ cells

    by Tiago Macedo, João Pedro Alves-Lopes

    BACKGROUND: Human-induced pluripotent stem cells (hiPSCs) offer immense potential in reproductive medicine, particularly for males who lack germ cells and cannot achieve biological parenthood through conventional ARTs. Early efforts to derive human germ cells from stem cells were hindered by low efficiency, subpar characterization, and the lack of standardized differentiation approaches. However, recent advancements have led to the development of defined protocols that mimic early embryonic development and allow the specification of transcriptomically and epigenetically validated human primordial germ cell-like cells (hPGCLCs). Current research focuses on maturing hPGCLCs in vitro, particularly within 3D culture systems that resemble their physiological microenvironment, with the aim of producing transplantable hiPSC-derived spermatogonial stem cells (SSCs) or differentiating them to sperm. At the same time, researchers are also testing whether hiPSCs generated from infertile patients can resume germline differentiation. OBJECTIVE AND RATIONALE: This narrative review aimed to summarize the key efforts and remaining challenges in differentiating male germ cells from human pluripotent stem cells (hPSCs), with a particular focus on defined and validated protocols for hPGCLC specification. In parallel, we addressed key safety and ethical considerations that must be accounted for the development of clinical applications. A deeper understanding of the approaching therapeutic use of hiPSCs in reproductive medicine is essential for developing novel regenerative fertility strategies. SEARCH METHODS: PubMed, Scopus, and Web of Science were searched for studies attempting germ cell differentiation from hPSCs using relevant keywords (‘stem cells’, ‘human pluripotent stem cells’, ‘human embryonic stem cells’, ‘human induced pluripotent stem cells’, ‘somatic cell reprogramming’, ‘infertility’, ‘germline’, ‘spermatogenesis’, ‘germ cells’, and ‘primordial germ cells’). No time period restriction was established. Studies with an exclusive focus on female germline differentiation were excluded. To maintain a human-focused perspective, only key animal studies are presented. OUTCOMES: The literature reveals a clear segregation among protocols for deriving germ cells from hPSCs, particularly between earlier studies lacking standardized differentiation conditions and characterization, and the most recent, defined protocols having transcriptomic and epigenetic validation against in vivo hPGCs. Moreover, during the last decade, the field has seen remarkable progress, with multiple efforts aimed at maturing hPGCLCs, closely recapitulating late male embryonic germline development. Additionally, hiPSCs derived from male patients at risk of infertility, particularly those without underlying genetic syndromes, generally retain the capacity for early germline commitment. While attempts at maturating patient germ cells beyond the hPGCLC state remain limited, the rapid pace of discovery and refinement in recent years suggests that further breakthroughs, including clinically applicable fertility restoration strategies, are likely to be achieved in the near future. WIDER IMPLICATIONS: The ability to generate hiPSCs from infertile patients and to specify them into hPGCLCs supports the feasibility of obtaining hiPSC-derived SSCs for future therapeutic use. These advances raise important ethical, regulatory, and societal questions that must be actively discussed among researchers, clinicians, policymakers, and the general public to ensure responsible and equitable access to these technologies. REGISTRATION NUMBER: N/A.


  • Open Access

    Non‐alkylating agents‐induced gonadotoxicity in pre‐pubertal males: Insights on the clinical and pre‐clinical front

    by Sruthi Sriram, Tiago Macedo, Annelies Mavinkurve‐Groothuis, Marianne van de Wetering, Leendert H. J. Looijenga

    Whilst chemotherapy regimens have proven to be more successful for pediatric cancer patients over the years, their influence on long‐term side effects is relatively poorly understood. One of the possible targets is the gonads, with gonadotoxic agents representing those that threaten the patient's ability to have children post surviving the primary disease treatment. Many risk stratification guidelines have categorized these agents based on the severity of their effect on the pre‐pubertal testis. While the consensus is that those agents factored with a cyclophosphamide equivalent dosage pose the highest threat to fertility (e.g. alkylating agents), other agents might still contribute to a reduced testis function; especially in the case of combination therapies. Besides, it is important to note that studies deciphering the effect of other non‐alkylating agents on the pre‐pubertal testis lack standardized conclusions for clinically relevant outcomes. This makes it imperative to ensure the knowledge gap is addressed between the clinic and pre‐clinic to understand potential gonadotoxic effects, ultimately leading to improved patient care. Therefore, this review will summarize the key findings in understanding the gonadotoxic effects of the most commonly researched non‐alkylating agents: vincristine, etoposide, doxorubicin, and imatinib on the pre‐pubertal testis.


  • Open Access

    Alkylating agents‐induced gonadotoxicity in prepubertal males: Insights on the clinical and preclinical front

    by Sruthi Sriram, Tiago Macedo, Annelies Mavinkurve‐Groothuis, Marianne van de Wetering, Leendert H. J. Looijenga

    Rising cure rates in pediatric cancer patients warrants an increased attention toward the long‐term consequences of the diagnosis and treatment in survivors. Chemotherapeutic agents can be gonadotoxic, rendering them at risk for infertility post‐survival. While semen cryopreservation is an option that can be provided for most (post)pubertal boys before treatment, this is unfortunately not an option prepubertal in age, simply due to the lack of spermatogenesis. Over the last couple of years, studies have thus focused on better understanding the testis niche in response to various chemotherapeutic agents that are commonly administered and their direct and indirect impact on the germ cell populations. These are generally compounds that have a high risk of infertility and have been classified into risk categories in curated fertility guidelines. However, with it comes the lack of evidence and the challenge of using informative models and conditions most reflective of the physiological scenario, in short, the appropriate study designs for clinically relevant outcomes. Besides, the exact mechanism(s) of action for many of these “risk” compounds as well as other agents is unclear. Understanding their behavior and effect on the testis niche will pave the way for incorporating new strategies to ultimately combat infertility. Of the various drug classes, alkylating agents pose the highest risk of gonadotoxicity as per previously established studies as well as risk stratification guidelines. Therefore, this review will summarize the findings in the field of male fertility concerning gonadotoxicity of akylating agents as a result of chemotherapy exposure.